help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tassignon, J.
Right arrow Articles by Haeseleer Abraham Borkowski, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tassignon, J.
Right arrow Articles by Haeseleer Abraham Borkowski, F.
The Journal of Clinical Endocrinology & Metabolism Vol. 82, No. 10 3464-3470
Copyright © 1997 by The Endocrine Society


Original Studies

Natural Antiestrogen Receptor Autoantibodies in Man with Estrogenic Activity in Mammary Carcinoma Cell Culture: Study of their Mechanism of Action; Evidence for Involvement of Estrogen-Like Epitopes1

Joël Tassignon and Françoise Haeseleer Abraham Borkowski

Service de Médecine, Laboratoire d’Investigation Clinique H. J. Tagnon, Laboratoire d’Endocrinologie, Institut Jules Bordet, Centre des Tumeurs de l’Université Libre de Bruxelles, B-1000 Brussels, Belgium

Address all correspondence and requests for reprints to: Abraham Borkowski, M.D., Service de Médecine, Institut Jules Bordet, 1 rue Héger-Bordet, B-1000 Bruxelles, Belgium.

We previously reported that human natural autoantibodies enriched in antiestrogen receptor Ig (IgGs) display estrogenic activity in MCF-7 mammary carcinoma cells. In this study, we investigated IgGs’ mechanism of action.

We showed that: 1) IgGs Fab fragments (which contain only one antigen binding site) induced an estrogenic response in MCF-7 cells, producing estrogen receptor (ER) down-regulation and an increase in progesterone receptor concentration; 2) IgGs specifically inhibited MCF-7 cell surface labeling with fluorescent estradiol (E2)-BSA conjugates; 3) this inhibition of E2-BSA binding to membrane estrogen binding sites was largely caused by natural anti-E2-BSA antibodies (Ab) selectively associated with the natural anti-ER Ab within IgGs; 4) furthermore, these natural anti-E2-BSA Ab accounted for most of IgGs estrogenic activity in cell culture; 5) however, when incubated with cytosolic ER, they did not behave like estrogens, but they decreased ER hormone binding capacity; and 6) although IgGs stimulated cAMP production, their anti-E2-BSA Ab subpopulation did not.

In conclusion, the estrogenic activity of IgGs does not involve Ab mimicking E2 molecular configuration or ligand-independent cAMP mediated pathways, membrane Fc receptors, and membrane receptor cross-linking mechanisms. On the contrary, IgGs seem to function by neutralizing estrogen-like epitopes, associated with ER-related peptides, which might inhibit ER activation.




This article has been cited by other articles:


Home page
J. Immunol.Home page
A. Nikoshkov, A. Falorni, S. Lajic, S. Laureti, A. Wedell, A. Lernmark, and H. Luthman
A Conformation-Dependent Epitope in Addison's Disease and Other Endocrinological Autoimmune Diseases Maps to a Carboxyl-Terminal Functional Domain of Human Steroid 21-Hydroxylase
J. Immunol., February 15, 1999; 162(4): 2422 - 2426.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1997 by The Endocrine Society